LT4192B - The use of fibrin-specific antibody as an antithrombic agent - Google Patents

The use of fibrin-specific antibody as an antithrombic agent Download PDF

Info

Publication number
LT4192B
LT4192B LT96-140A LT96140A LT4192B LT 4192 B LT4192 B LT 4192B LT 96140 A LT96140 A LT 96140A LT 4192 B LT4192 B LT 4192B
Authority
LT
Lithuania
Prior art keywords
fibrin
monoclonal antibody
thrombotic
specific
vascular disease
Prior art date
Application number
LT96-140A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT96140A (en
Inventor
Paul E Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of LT96140A publication Critical patent/LT96140A/xx
Publication of LT4192B publication Critical patent/LT4192B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LT96-140A 1994-02-24 1996-09-24 The use of fibrin-specific antibody as an antithrombic agent LT4192B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody

Publications (2)

Publication Number Publication Date
LT96140A LT96140A (en) 1997-03-25
LT4192B true LT4192B (en) 1997-07-25

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
LT96-140A LT4192B (en) 1994-02-24 1996-09-24 The use of fibrin-specific antibody as an antithrombic agent

Country Status (26)

Country Link
US (1) US5487892A (fi)
EP (1) EP0749320A4 (fi)
JP (1) JPH09509429A (fi)
KR (1) KR970701063A (fi)
CN (1) CN1146157A (fi)
AU (1) AU708897B2 (fi)
BG (1) BG62476B1 (fi)
BR (1) BR9506949A (fi)
CA (1) CA2183953A1 (fi)
CZ (1) CZ246496A3 (fi)
FI (1) FI963288A (fi)
GE (1) GEP20002257B (fi)
HU (1) HUT76536A (fi)
LT (1) LT4192B (fi)
LV (1) LV11784B (fi)
MD (1) MD1521G2 (fi)
MX (1) MX9603602A (fi)
NO (1) NO963497L (fi)
NZ (1) NZ281481A (fi)
PL (1) PL316005A1 (fi)
RU (1) RU2152801C2 (fi)
SG (1) SG53279A1 (fi)
SK (1) SK108496A3 (fi)
TJ (1) TJ301B (fi)
UA (1) UA41984C2 (fi)
WO (1) WO1995022986A1 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US7829294B2 (en) * 2004-12-28 2010-11-09 Daiichi Pure Chemicals Co., Ltd. Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
EP2704751B1 (en) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
AU7912887A (en) * 1986-08-25 1988-03-24 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
EP0710720A1 (en) * 1988-06-13 1996-05-08 American Biogenetic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ELMS MJ,: "Measurement of crosslinked fibrin derivatives in plasma: an immunoassay psing monoclonal antibodies", J CLIN PATHOL., 1983, pages 591 - 594
FRANKEL ME, GERHARD W.: "The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay", MOL IMMUNOL, 1979, pages 101 - 106, XP023680155, DOI: 10.1016/0161-5890(79)90051-8
FUSTER V. AND VERSTRAETE M.: "Thrombosis in Cardiovascular Disorders", pages: 1 - 16
GARGAN PE ET AL.: "A monoclonal antibody which recognizes an epitopic region unique to the intact fibrin polymeric structure", FIBRINOLYSIS, 1993, pages 275 - 283
GIMPLE LW ET AL.: "Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits. A quantitative angiographic and histopathological study", CIRCULATION, 1992, pages 1536 - 1546
GIMPLE LW ET AL.: "Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits. A quantitative angiographic and histopathological study.", CIRCULATION, 1992, pages 1536 - 1546
HOOTS W.K. ET AL.: "A Naturally Occurring Antibody That Inhibits Fibrin Polymerization", N ENGL J MED, 1981, pages 857 - 861, XP000197135
KHAW BA ET AL.: ""Magic bullets:" from muskets to smart bombs!!!", J NUCL MED., 1993, pages 2264 - 2268
NIEUWENHUIZEN W: "Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review", BLOOD COAGUL FIBRINOLYSIS, 1993, pages 93, XP001029604, DOI: 10.1097/00001721-199304010-00015
PARHAM P ET AL.: "Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens.", J IMMUNOL METHODS, 1983, pages 133 - 173
SAREMBOCK IJ ET AL.: "Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. A study in the atherosclerotic rabbit.", CIRCULATION, 1989, pages 1029 - 1040
TENAGLIA AN, STACK RS: "Angioplasty for acute coronary syndromes", ANNU REV MED, 1993, pages 465 - 479

Also Published As

Publication number Publication date
JPH09509429A (ja) 1997-09-22
EP0749320A4 (en) 1997-06-18
AU1843495A (en) 1995-09-11
NO963497D0 (no) 1996-08-22
MD960334A (en) 1997-09-30
CZ246496A3 (en) 1997-04-16
EP0749320A1 (en) 1996-12-27
BG62476B1 (bg) 1999-12-30
LV11784B (en) 1997-12-20
WO1995022986A1 (en) 1995-08-31
MD1521F2 (en) 2000-08-31
HUT76536A (en) 1997-09-29
MX9603602A (es) 1997-05-31
NO963497L (no) 1996-10-16
CA2183953A1 (en) 1995-08-31
BG100863A (en) 1997-08-29
UA41984C2 (uk) 2001-10-15
SG53279A1 (en) 1998-09-28
AU708897B2 (en) 1999-08-12
GEP20002257B (en) 2000-10-25
FI963288A0 (fi) 1996-08-23
US5487892A (en) 1996-01-30
NZ281481A (en) 1998-07-28
TJ301B (en) 2001-08-06
PL316005A1 (en) 1996-12-23
FI963288A (fi) 1996-08-23
LT96140A (en) 1997-03-25
BR9506949A (pt) 1997-09-23
KR970701063A (ko) 1997-03-17
RU2152801C2 (ru) 2000-07-20
HU9602337D0 (en) 1996-10-28
SK108496A3 (en) 1997-10-08
CN1146157A (zh) 1997-03-26
LV11784A (lv) 1997-06-20
MD1521G2 (ro) 2001-03-31

Similar Documents

Publication Publication Date Title
US6294173B1 (en) Methods for treating a tumor containing fibrin using a fibrin specific monoclonal antibody and compositions used therein
ES2380452T3 (es) Anticuerpos para inhibir la coagulación de la sangre y métodos de utilización de los mismos
US7754215B2 (en) Antithrombotic therapy with antibodies binding to the A3 domain of von Willebrand factor (VWF)
US6280731B1 (en) Antithrombotic agent and anti-von willebrand factor monoclonal antibody
US20200129600A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
JPH03505329A (ja) 心筋梗塞の処置のための方法および治療用組成物
LT4192B (en) The use of fibrin-specific antibody as an antithrombic agent
US20090010934A1 (en) Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
EP3260133A1 (en) Antibodies against mac-1
JPH04228088A (ja) 血小板因子４の生物学的作用を阻害するモノクローナル抗体
US20090311267A1 (en) Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks
WO1996040986A1 (en) Calibrator for use in a soluble fibrin assay

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20020221